1-(5-Methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)furan-2-yl)piperidine

Catalog No. :
ACXZXS217
CAS No. :
2223042-98-4
Molecular Formula :
C16H26BNO3
Molecular Weight :
291.20

IUPAC Name:1-(5-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)furan-2-yl)piperidine

1-(5-Methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)furan-2-yl)piperidine structure diagram
Pack SizePurityList PriceYour PriceGlobal StockUS StockQuantity
No pack options available.

Products of AiFChem are all designed for scientific research only. Under no circumstances do we provide products or services for animal or personal utilization.

Product Information

Product Name1-(5-Methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)furan-2-yl)piperidine
IUPAC Name1-(5-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)furan-2-yl)piperidine
Molecular FormulaC16H26BNO3
Molecular Weight291.20
SMILESCC(OC(N1CCCCC1)=C2)=C2B3OC(C)(C)C(C)(C)O3
InChI KeyJSENEQKPUBIZIX-UHFFFAOYSA-N
Synonym2-Methyl-5-(piperidino)furan-3-boronic acid pinacol ester;Piperidine, 1-[5-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-2-furanyl]-
CAS No.2223042-98-4

Safety Data

Pictogram
Harmful or irritant
Signal Word
Achtung
Hazard Statement(s)
H302-H315-H319-H335
Precautionary Statement(s)
P261-P264-P270-P271-P280-P301+P312-P302+P352-P304+P340-P305+P351+P338-P330-P332+P313-P337+P313-P362-P403+P233-P405-P501

Synthetic Route by SureRoute

1. ACXZXS217 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. ACTOBU801 route compound structure diagram
    ACTOBU80173183-34-3 In Stock
  2. Plus
  3. reactant_2 route compound structure diagram
    --
  4. Then
  5. ACXZXS217 route product structure diagram
    ACXZXS2172223042-98-4
Inquiry

2. ACXZXS217 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Plus
  3. reactant_2 route compound structure diagram
    --
  4. Then
  5. ACXZXS217 route product structure diagram
    ACXZXS2172223042-98-4
Inquiry

Comments (0)